Drug Action
Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine.
PDF page 75
Loading InternPractice…
Drug reference
Teduglutide is an analogue of human glucagon-like peptide-2 (GLP-2), which preserves mucosal integrity by promoting growth and repair of the intestine.
PDF page 75
Short bowel syndrome (initiated under specialist supervision) ▶BY SUBCUTANEOUS INJECTION ▶Adult: 0.05 mg/kg once daily, dose to be administered to alternating quadrants of the abdomen; alternatively the thigh can be used, for optimal injection volume per body weight, consult product literature. Review treatment after 6 months
PDF page 75
Active or suspected malignancy. history of gastro-intestinal malignancy (in previous 5 years)
PDF page 75
Abrupt withdrawal of parenteral support (reduce gradually with concomitant monitoring of fluid status). cardiac insufficiency. cardiovascular disease. colo-rectal polyps. hypertension
PDF page 75
Manufacturer advises caution in patients with tetracycline hypersensitivity.
PDF page 76
Scottish Medicines Consortium (SMC) decisions SMC No. SMC2225 The Scottish Medicines Consortium has advised (February 2020) that teduglutide (Revestive ®) is accepted for use within NHS Scotland for the treatment of adults with short bowel syndrome. Patients should be stable following a period of intestinal adaptation after surgery. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower.
PDF page 76
▶Common or very common Anxiety. appetite decreased. congestive heart failure. cough. dyspnoea. fluid imbalance. gallbladder disorders. gastrointestinal discomfort. gastrointestinal disorders. gastrointestinal stoma complication. headache. influenza like illness. insomnia. nausea. pancreatitis. peripheral oedema. respiratory tract infection. vomiting ▶Uncommon Syncope
PDF page 75
g Specialist sources indicate use if Gastro-intestinal system necessary—no human data available. k
PDF page 76
Manufacturer advises avoid—toxicity in animal studies.
PDF page 76
Dose adjustments Manufacturer advises use half the daily dose in moderate or severe impairment and end-stage renal disease.
PDF page 76
Manufacturer advises monitoring of small bowel function, gall bladder, bile ducts and pancreas during treatment.
PDF page 76
There can be variation in the licensing of different medicines containing the same drug. Powder and solvent for solution for injection ▶Revestive (Shire Pharmaceuticals Ltd) A Teduglutide 1.25 mg Revestive 1.25mg powder and solvent for solution for injection vials | 28 vial P £7,307.70 Teduglutide 5 mg Revestive 5mg powder and solvent for solution for injection vials | 28 vial P £14,615.39 Constipation and bowel cleansing 2.1 Bowel cleansing Other drugs used for Bowel cleansing Bisacodyl, p. 65. Docusate sodium, p. 65. Magnesium sulfate, p. 1112 LAXATIVES › OSMOTIC LAXATIVES
PDF page 76
Caution when discontinuing treatment—risk of dehydration.
PDF page 76
Patients with cardiovascular disease should seek medical attention if they notice sudden weight gain, swollen ankles or dyspnoea—may indicate increased fluid absorption.
PDF page 76
0.05 mg/kg once daily, dose to be administered
First-line fragment. Read the complete Indications and Dose section above.
PDF page 75